HERAMED LIMITED — Capital/Financing Update 2021

Nov 14, 2021

==> picture [535 x 49] intentionally omitted <==

15 November 2021

HeraMED Limited (ASX:HMD) (" HeraMED " or the " Company "), refers to its recent capital raising announced on 18 October 2021 where HeraMED issued 2,392,047 convertible notes (" Convertible Notes ") at a face value of $1.00.

The conversion of the Convertible Notes into ordinary shares in the Company (" Share ") are subject to a floor of $0.09 cents per Share on conversion. Interest under the Convertible Notes accrues at a rate of 10% p.a. and is capitalised and to be paid in additional Shares to be issued at conversion of the Convertible Notes, at the relevant conversion price. The maximum number of Shares that may be issued with respect to the interest capitalised under the current terms of the Convertible Notes is 1,328,914 Shares.

The Company advises that:

1. The Company has exceeded its capacity to issue and agreed to issue equity securities without security holder approval under listing rule 7.1 by 1,328,914 equity securities, being the interest component of the Convertible Notes.

2. Ratification by security holders of the issue of the 1,328,914 equity securities will not refresh the Company’s capacity to issue securities without security holder approval under listing rule 7.1, as ratification under listing rule 7.4 is only available where the securities are issued without breaching listing rule 7.1.

3. The Company has not issued any equity securities without security holder approval between 18 October 2021 and 5 November 2021.

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited Company Secretary Investor Enquiries CEO and Co-Founder Jonathan Hart PAC Partners David Groberman T: +61 2 7251 1888 Tim Chapman M: +972 52 6991188 E: Jonathan@hera-med.com T: 61 419 897 062 E: David@hera-med.com E: tchapman@pacpartners.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data, and a digital social networking dashboard.

HeraMED Limited ACN 626 295 314 T: +61 2 8379 2961 | A: Suite 3, Level 10, 23-25 Hunter Street SYDNEY NSW 2000

Page 1